193 related articles for article (PubMed ID: 10399506)
21. Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Fragmin in Unstable Coronary Artery Disease.
Klein W; Buchwald A; Hillis WS; Monrad S; Sanz G; Turpie AG; van der Meer J; Olaisson E; Undeland S; Ludwig K
Am J Cardiol; 1997 Sep; 80(5A):30E-34E. PubMed ID: 9296467
[TBL] [Abstract][Full Text] [Related]
22. Approaches to the treatment of unstable angina and non-Q wave myocardial infarction.
Cohen M
Can J Cardiol; 1998 Aug; 14 Suppl E():11E-14E. PubMed ID: 9779027
[TBL] [Abstract][Full Text] [Related]
23. Head-to-head comparison of two different low-molecular-weight heparins in acute coronary syndrome: a single center experience.
Ozdemir M; Erdem G; Türkoglu S; Cemri M; Timurkaynak T; Boyaci B; Ridvan Y; Cengel A; Dörtlemez O; Dörtlemez H
Jpn Heart J; 2002 Sep; 43(5):433-42. PubMed ID: 12452301
[TBL] [Abstract][Full Text] [Related]
24. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
[TBL] [Abstract][Full Text] [Related]
25. New-generation anticoagulants: the low molecular weight heparins.
Hovanessian HC
Ann Emerg Med; 1999 Dec; 34(6):768-79. PubMed ID: 10577408
[TBL] [Abstract][Full Text] [Related]
26. Low-molecular-weight heparins in acute unstable coronary artery disease - an update.
Turpie AG
Haemostasis; 1999 Dec; 29 Suppl S1():72-5. PubMed ID: 10629408
[TBL] [Abstract][Full Text] [Related]
27. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
[TBL] [Abstract][Full Text] [Related]
28. Low-molecular-weight heparins in the management of acute coronary syndromes.
Zed PJ; Tisdale JE; Borzak S
Arch Intern Med; 1999 Sep; 159(16):1849-57. PubMed ID: 10493315
[TBL] [Abstract][Full Text] [Related]
29. [The role of low-molecular-weight heparin in unstable angina, acute myocardial infarction and post-elective percutaneous transluminal coronary angioplasty].
Cláudio Correia LC; Neubauer C; Azevedo A; Ribeiro F; Braga J; Carlos Passos L; Teixeira M; Matos M; Aires V; Souza V
Arq Bras Cardiol; 1995 Dec; 65(6):475-8. PubMed ID: 8731298
[TBL] [Abstract][Full Text] [Related]
30. Low-molecular-weight heparin: an antithrombotic agent whose time has come.
Futterman LG; Lemberg L
Am J Crit Care; 1999 Jan; 8(1):520-3. PubMed ID: 9987551
[TBL] [Abstract][Full Text] [Related]
31. Low molecular weight heparin in acute coronary syndromes.
Cannon CP
Curr Cardiol Rep; 1999 Sep; 1(3):206-11. PubMed ID: 10980843
[TBL] [Abstract][Full Text] [Related]
32. Low molecular weight heparins in the treatment of unstable angina.
Ageno W; Turpie AG
Minerva Cardioangiol; 2002 Dec; 50(6):643-51. PubMed ID: 12473984
[TBL] [Abstract][Full Text] [Related]
33. Antithrombotic therapy in unstable angina/non-ST elevation myocardial infarction: the evolving role of low-molecular-weight heparin.
Antman EM; Kereiakes DJ
J Invasive Cardiol; 2000 Dec; 12 Suppl E():E1-4;discussion E25-8. PubMed ID: 11156721
[TBL] [Abstract][Full Text] [Related]
34. Low-molecular-weight heparin should replace unfractionated heparin in the management of acute coronary syndromes.
Zed PJ
J Thromb Thrombolysis; 1999 Aug; 8(2):79-87. PubMed ID: 10436138
[TBL] [Abstract][Full Text] [Related]
35. Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials.
Fox KA
Am J Cardiol; 1999 Sep; 84(5A):26M-31M. PubMed ID: 10505540
[TBL] [Abstract][Full Text] [Related]
36. Therapy of unstable angina with the low molecular weight heparins.
Ageno W; Turpie AG
Vasc Med; 2000; 5(4):217-23. PubMed ID: 11213233
[TBL] [Abstract][Full Text] [Related]
37. [Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina].
Godoy I; Herrera C; Zapata C; Kunstmann S; Abufhele A; Corbalán R
Rev Med Chil; 1998 Mar; 126(3):259-64. PubMed ID: 9674294
[TBL] [Abstract][Full Text] [Related]
38. ESSENCE trial results: breaking new ground. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events.
Demers C
Can J Cardiol; 1998 Aug; 14 Suppl E():15E-19E. PubMed ID: 9779028
[TBL] [Abstract][Full Text] [Related]
39. A critical review of clinical trials for low-molecular-weight heparin therapy in unstable coronary artery disease.
Husted S; Becker R; Kher A
Clin Cardiol; 2001 Jul; 24(7):492-9. PubMed ID: 11444639
[TBL] [Abstract][Full Text] [Related]
40. The role of low-molecular-weight heparin in the management of acute coronary syndromes.
Cohen M
J Am Coll Cardiol; 2003 Feb; 41(4 Suppl S):55S-61S. PubMed ID: 12644342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
